{{my.ViewAsWebpage Title}}
Meet Penumbra @ CIRSE 2023
Copenhagen, Denmark | 9 – 13 September, 2023
Firstline Management of ALI: Primary Endpoint Results from STRIDE 30-day Analysis, Economic Perspectives, Clinical Case Review with Computer-Aided Thrombectomy, and Results from INDIAN-UP

Sunday, 10 September | 16:45 – 17:05 CET | Room 20
STRIDE Study Outcomes and an Economic Comparison of Treating ALI with CDT vs. Mechanical Aspiration Thrombectomy

Dr. Rafiuddin (Raf) Patel
John Radcliffe Hospital, United Kingdom

Interim Results of the INDIAN-UP Trial and Acute Limb Ischemia Case Discussion

Prof. Gianmarco de Donato
Università di Siena, Italy
Innovations in the Treament of Pulmonary Embolism and Management of Deep Vein Thrombosis with Computer-Aided Thrombectomy: Clinical Study Advancements and Case Review

Monday, 11 September | 13:00 – 14:00 CET | Auditorium 15
Prof. Christoph Binkert
Kantonsspital Winterthur, Switzerland

Introduction to the Session
The History of Aspiration

Pulmonary Embolism - Primary Percutaneous Treatment of PE with Lightning™ 12 Intelligent Aspiration: Clinical Update and Experience

Current Status of Pulmonary Embolism Management

Prof. Stavros Konstantinides
Universitätsmedizin Mainz, Germany

Clinical Evidence: EXTRACT-PE, Interim STRIKE-PE Study Results and STORM-PE
Utilizing Lightning 12 for Primary Percutaneous ?Treatment of Pulmonary Embolism

Dr. John Moriarty
UCLA, Los Angeles, USA

DVT - Can Early Thrombus Removal Improve the Outcomes for DVT Patients?

Current Status of DVT Management
Iliofemoral DVT Case Discussions

Dr. Kush Desai
Northwestern University Feinberg School of Medicine. Chicago, United States

Current Status of DVT Management
Upper Limb DVT Case Discussions

Prof. Gerry O'Sullivan
University Hospital Galway, Ireland
Physician images used with permission. Consents on file at Penumbra, Inc.

Product availability varies by country. Prior to use, please refer to the Instructions for Use (IFU) for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Please click here for the complete IFU Risk Statements. Please contact your local Penumbra representative for more information.

Copyright ©2023 Penumbra, Inc. All rights reserved. The Penumbra P logos and Lightning are registered trademarks or trademarks of Penumbra, Inc. in the USA and other countries. 24572, Rev. B 08/23 OUS